These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35273352)

  • 1. Sacubitril/valsartan-A new weapon for fighting the hypertension paradox.
    Ohishi M
    Hypertens Res; 2022 May; 45(5):915-916. PubMed ID: 35273352
    [No Abstract]   [Full Text] [Related]  

  • 2. Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
    Volpe M; Gallo G
    Eur Heart J; 2021 Sep; 42(36):3753-3755. PubMed ID: 34392358
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical case: early connection of valsartan/sacubitril in the treatment of hypertension].
    Lozhkina NG; Spiridonov AN
    Kardiologiia; 2022 May; 62(5):72-74. PubMed ID: 35692177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
    Pfeffer MA; Claggett B; Lewis EF; Granger CB; Køber L; Maggioni AP; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Steg PG; Berwanger O; Cikes M; De Pasquale CG; Fernandez A; Filippatos G; Jering K; Landmesser U; Menon V; Merkely B; Petrie MC; Petrov I; Schou M; Senni M; Sim D; van der Meer P; Lefkowitz M; Zhou Y; Wang Y; Braunwald E
    Circulation; 2022 Jan; 145(1):87-89. PubMed ID: 34797725
    [No Abstract]   [Full Text] [Related]  

  • 6. The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
    Crea F
    Eur Heart J; 2021 Sep; 42(36):3581-3585. PubMed ID: 34549264
    [No Abstract]   [Full Text] [Related]  

  • 7. [Sacubitril-valsartan should also be the first choice to be evaluated in the elderly patient with heart failure with reduced ejection fraction].
    Camafort M; Formiga F
    Rev Esp Geriatr Gerontol; 2021; 56(2):67-68. PubMed ID: 33526274
    [No Abstract]   [Full Text] [Related]  

  • 8. [Update on the clinical application of valsartan/sacubitril in patients with heart failure].
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jun; 45(6):538-541. PubMed ID: 28648033
    [No Abstract]   [Full Text] [Related]  

  • 9. Sacubitril/Valsartan: Practice Changing Guideline in the Management of Congestive Heart Failure.
    Karim MA; Siddiqui HU; Ullah S; Khan NAJ
    J Coll Physicians Surg Pak; 2017 Nov; 27(11):733. PubMed ID: 29132491
    [No Abstract]   [Full Text] [Related]  

  • 10. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
    Jackson AM; Jhund PS; Anand IS; Düngen HD; Lam CSP; Lefkowitz MP; Linssen G; Lund LH; Maggioni AP; Pfeffer MA; Rouleau JL; Saraiva JFK; Senni M; Vardeny O; Wijkman MO; Yilmaz MB; Saito Y; Zile MR; Solomon SD; McMurray JJV
    Eur Heart J; 2021 Sep; 42(36):3741-3752. PubMed ID: 34392331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study.
    Felker GM; Butler J; Januzzi JL; Desai AS; McMurray JJV; Solomon SD
    Circulation; 2021 Jun; 143(23):2316-2318. PubMed ID: 34097449
    [No Abstract]   [Full Text] [Related]  

  • 12. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
    Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S
    Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of Sacubitril/Valsartan on Right Heart Failure.
    Imamura T; Hori M; Ueno H; Kinugawa K
    Int Heart J; 2021 Jul; 62(4):932-934. PubMed ID: 34276024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
    Huet F; Akodad M; Kalmanovitch E; Adda J; Agullo A; Batistella P; Roubille C; Roubille F
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):1-10. PubMed ID: 30345485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In brief: Sacubitril/valsartan (Entresto) expanded indication.
    Med Lett Drugs Ther; 2021 May; 63(1623):65. PubMed ID: 33976096
    [No Abstract]   [Full Text] [Related]  

  • 16. Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure.
    Solomon SD; McMURRAY JJV
    J Card Fail; 2021 Jun; 27(6):693-695. PubMed ID: 33872760
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
    Seferovic JP; Claggett B; Seidelmann SB; Seely EW; Packer M; Zile MR; Rouleau JL; Swedberg K; Lefkowitz M; Shi VC; Desai AS; McMurray JJV; Solomon SD
    Lancet Diabetes Endocrinol; 2017 May; 5(5):333-340. PubMed ID: 28330649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Application of Sacubitril/Valsartan in Heart Failure.
    Liu X; Zhong L
    Am J Ther; 2021 Apr; 28(4):e511-e513. PubMed ID: 33852477
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experience of hospital initiation of sacubitril/valsartan in a female patient after acute decompensated heart failure].
    Galochkin SA; Lukina OI; Meraĭ IA; Villevalde SV; Kobalava ZD
    Kardiologiia; 2018 SMay; (S5):60-64. PubMed ID: 29894678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.